United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $593.99, for a total transaction of $5,642,905.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $192,715,897.57. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Trading Down 0.4%

Shares of NASDAQ UTHR opened at $593.31 on Friday. United Therapeutics Corporation has a 1-year low of $455.63 and a 1-year high of $614.23. The company has a market cap of $25.27 billion, a PE ratio of 22.39, a P/E/G ratio of 3.99 and a beta of 0.49. The company has a 50-day moving average of $540.58 and a two-hundred day moving average of $535.80.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. During the same period last year, the company earned $7.16 earnings per share. United Therapeutics’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.90 earnings per share for the current year.

United Therapeutics declared that its board has authorized a stock repurchase program on Thursday, October 22nd that authorizes the company to repurchase $2 billion in outstanding shares. This repurchase authorization authorizes the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Institutional Trading of United Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Meeder Advisory Services Inc. boosted its position in shares of United Therapeutics by 3.0% in the 3rd quarter. Meeder Advisory Services Inc. now owns 657 shares of the biotechnology company’s stock worth $356,000 after purchasing an additional 19 shares during the last quarter. Benjamin Edwards Inc. increased its holdings in United Therapeutics by 5.1% in the third quarter. Benjamin Edwards Inc. now owns 497 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 24 shares during the last quarter. First Trust Advisors LP increased its holdings in United Therapeutics by 40.4% in the third quarter. First Trust Advisors LP now owns 349,666 shares of the biotechnology company’s stock valued at $189,480,000 after purchasing an additional 100,610 shares during the last quarter. Allianz SE bought a new stake in United Therapeutics in the third quarter valued at about $182,000. Finally, Advisors Asset Management Inc. acquired a new position in United Therapeutics in the third quarter valued at about $23,850,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Recent United Therapeutics Headlines

Here are a few of the latest headlines about UTHR:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target. Its forecasts point to rising EPS, from $27.46 in FY2026 to $53.67 in FY2030, suggesting expectations for substantial longer-term earnings growth. HC Wainwright coverage article
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.64 million, reducing her direct stake by 2.84%; she still owns about 324,443 shares. Director Christopher Patusky also sold 1,210 shares for $701,800, a 36.12% reduction in his position. Insider selling can create a near-term sentiment overhang, although it does not by itself indicate a change in the company’s outlook. CEO sale report Director sale report

Wall Street Analysts Forecast Growth

A number of research analysts have commented on UTHR shares. JPMorgan Chase & Co. decreased their price objective on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 28th. Raymond James Financial set a $720.00 price target on United Therapeutics in a report on Wednesday, November 4th. Wells Fargo & Company lifted their price objective on United Therapeutics from $700.00 to $703.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. BTIG Research boosted their price objective on United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Finally, Leerink Partners boosted their price objective on United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $676.40.

United Therapeutics Company Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.